(Total Views: 74)
Posted On: 07/18/2025 10:53:12 AM
Post# of 29851
$ABP - As of July 2025, Abpro Corp. (NASDAQ: ABP) has a public float of approximately 30.19 million shares.
Abpro is a biotech company developing next-generation antibody therapies for:
Cancer (immuno-oncology)
Ophthalmology (eye diseases)
They use two proprietary platforms:
DiversImmune™ – Generates a wide range of antibodies against both known and novel disease targets.
MultiMab™ – Allows flexible engineering of multi-specific antibodies, combining different antibody fragments into one therapy.
Abpro is a biotech company developing next-generation antibody therapies for:
Cancer (immuno-oncology)
Ophthalmology (eye diseases)
They use two proprietary platforms:
DiversImmune™ – Generates a wide range of antibodies against both known and novel disease targets.
MultiMab™ – Allows flexible engineering of multi-specific antibodies, combining different antibody fragments into one therapy.
(0)
(0)
